Human cytomegalovirus (HCMV), a betaherpesvirus, is pathogenic almost exclusively in immunocompromised individuals. Cellular immune response is thought to control HCMV in immunocompetent people, both in the acute phase and in the latent infection which ensues (for a review, see reference 6). Cytotoxic CD8+ T cells contribute greatly to immunological control, as revealed by the presence of cytotoxic CD8+ T cells in patients who recover from acute infections (37) and by the prevention of HCMV disease following the injection of viral matrix-specific CD8+ clones to bone marrow transplant patients (44). CD4+ T cells against HCMV proteins have also been described (4, 12, 28), and a significant response towards IE1, the major immediate-early DNA-binding protein, has been reported (3, 9). The precursor frequencies of IE1-specific CD4+ T cells are high in latently infected individuals (9), and cytokines such as gamma interferon (IFN-γ) and tumor necrosis factor alpha (TNF-α) found in the supernatant of CD4+ T-cell clones specific for IE1 significantly reduce HCMV replication (10). The role of CD4+ T cells in HCMV infections was inferred from these in vitro studies and from in vivo studies showing that CD4+ T cells are required for the clearance of mouse cytomegalovirus (MCMV) in salivary glands of mice (22). Major histocompatibility complex (MHC) class II expression is a key element in the control of the immune response. It is required for the activation of T lymphocytes in the process of antigen (Ag) presentation by professional or nonprofessional antigen-presenting cells (APC) (13). Three essential transactivators of MHC class II genes have been identified: RFX5 and RFX-AP are part of the RFX complex that binds to the X box of all MHC class II promoters, while the class II transactivator (CIITA) is itself tightly regulated, and this transactivator functions as the master controller of MHC class II expression, probably in all physiological conditions (30, 42). Both constitutive and inducible expressions of MHC class II genes are indeed dependent on CIITA, and the CIITA gene is itself controlled by distinct alternative promoters (33). While CIITA promoters I and III are specific for constitutive expression in dendritic cells and B lymphocytes, respectively, induction of CIITA, and hence of MHC class II, by IFN-γ is mediated by promoter IV. Activation by IFN-γ takes place via a cascade of events which involves tyrosine phosphorylation of STAT1 by JAK1 and JAK2 kinases, followed by nuclear translocation and binding of STAT1 to a GAS sequence within the promoter of the target gene (reviewed in reference 8). In the case of the activation of CIITA promoter IV by IFN-γ, cooperation between three distinct and essential transacting factors, STAT1 and USF-1 (binding cooperatively to a GAS-E box motif) and IRF-1, has recently been described in detail (34). This also explains why JAK1 and STAT1 mutants lack inducibility of MHC class II by IFN-γ (31). The detailed dissection of these multiple steps of the cascade, from IFN-γ activation to expression of MHC class II molecules (33, 34), now allows the assignment of various types of inhibition to specific steps within this cascade. APC capacity is triggered by IFN-γ treatment in many cell types, due to the induction of expression of HLA class II, the invariant chain, and HLA-DM which catalyzes the release of invariant chain-derived Clip peptide from HLA class II molecules and allows the binding of processed peptides (36). MHC class II molecules are known to present peptides derived from extracellular, exogenous Ag to CD4+ T cells (36). However, it appears that presentation of intracellular endogenous, especially viral, Ags is common (14, 23). This suggests cognate interaction between CD4+ T cell and the infected MHC class II-positive APC. Immunological controls of cytomegaloviruses are counterbalanced by escape mechanisms from class I-mediated recognition by CD8+ T cells, as recently described (46). Several genes localized in the unique short (US) region of the HCMV genome are responsible for down regulating HLA class I expression at multiple levels through retrotranslocation of HLA class I heavy chain to the cytosol (US2 [19, 47] and US11 [21, 45]), retention in the endoplasmic reticulum (US3 [1, 20]) and inhibition of TAP translocation of peptides (US6 [2, 17, 26]). The CD4+ compartment of cellular immunity has been suspected to be down regulated since the observation by Sedmak et al. (38) that HCMV inhibits HLA class II expression induced by IFN-γ. A recent report by Miller et al. (32) has described a mechanism of JAK1 proteolysis by HCMV to explain the inhibition of IFN-γ-mediated induction of HLA class II. In mice, Heise et al. (15) have reported that MCMV down regulates IFN-γ-induced expression of MHC class II-related molecules through the inhibition of their transcription. The mechanism, which occurs downstream of STAT1 activation, has yet to be determined. In this paper, we made use of an astrocytoma cell line, U373 MG, which is fully permissive to HCMV. This cell line can also be induced to express HLA-DR by treatment with IFN-γ and to subsequently present Ag to HCMV IE1-specific CD4+ T cells (11). We show here that HCMV infection prevents induction of HLA-DR expression by IFN-γ in U373 MG cells. This inhibition occurs downstream of the activation of STAT1, whose phosphorylation and nuclear translocation are not inhibited by HCMV. CIITA transcription is strongly repressed by cotreatment of cells with IFN-γ plus HCMV. Logically, this strong reduction of MHC class II expression by HCMV results in the absence of IE1 presentation and recognition by CD4+ T-cell clones. Transfection of the U373 MG cells by CIITA, however, can restore both HLA-DR expression and the ability to present endogenously produced IE1 to CD4+ T cells, even following HCMV infection. These results indicate that, in IFN-γ-treated cells, down regulation of MHC class II expression by HCMV results from a repression of CIITA induction. The modulation of MHC class II-dependent IE1 recognition by viral infection, via an effect on CIITA expression, can thus allow HCMV-infected cells to escape from the CD4+ T-cell response.